{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T04:08:06Z","timestamp":1751515686198,"version":"3.41.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Academician\u00a0Expert\u00a0Workstation\u00a0Grants","award":["20R9004076411"],"award-info":[{"award-number":["20R9004076411"]}]},{"name":"Shanghai science and technology support project on biomedicine in the action plan of Science and Technology Innovation","award":["19431904200"],"award-info":[{"award-number":["19431904200"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s11095-025-03863-x","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T21:06:05Z","timestamp":1746738365000},"page":"917-933","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Preclinical Toxicity Study and Tissue Distribution of YSCH- 01 Injection via Intratumoral Injection, Intravenous Injection, and Intraperitoneal Injection in Syrian Hamsters"],"prefix":"10.1007","volume":"42","author":[{"given":"Ruoyu","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xian-Long","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hafiz Khuram","family":"Raza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"key":"3863_CR1","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3389\/fonc.2017.00202","volume":"7","author":"SR Jhawar","year":"2017","unstructured":"Jhawar SR, Thandoni A, Bommareddy PK, Hassan S, Kohlhapp FJ, Goyal S, Schenkel JM, Silk AW. Zloza A Oncolytic Viruses-Natural and Genetically Engineered Cancer Immunotherapies. Front Oncol. 2017;7:202. https:\/\/doi.org\/10.3389\/fonc.2017.00202.","journal-title":"Front Oncol."},{"issue":"9","key":"3863_CR2","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1007\/s00705-017-3411-4","volume":"162","author":"KK Sharma","year":"2017","unstructured":"Sharma KK, Kalyani IH, Mohapatra J, Patel SD, Patel DR, Vihol PD, Chatterjee A, Patel DR, Vyas B. Evaluation of the oncolytic potential of R2B Mukteshwar vaccine strain of Newcastle disease virus (NDV) in a colon cancer cell line (SW-620). Arch Virol. 2017;162(9):2705\u201313. https:\/\/doi.org\/10.1007\/s00705-017-3411-4.","journal-title":"Arch Virol."},{"issue":"1","key":"3863_CR3","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","volume":"8","author":"L Danni","year":"2023","unstructured":"Danni L, Yinan S, Tingbo L. Oncolytic virotherapy: basic principles, recent advances and future directions. Signal Transduct Target Ther. 2023;8(1):156.","journal-title":"Signal Transduct Target Ther."},{"key":"3863_CR4","doi-asserted-by":"crossref","unstructured":"Lingjuan C, Mengsi Z, Qin Z, Yang W. Oncolytic virotherapy in cancer treatment: challenges and optimization prospects. Front Immunol. 2024;14(0).","DOI":"10.3389\/fimmu.2023.1308890"},{"key":"3863_CR5","doi-asserted-by":"publisher","first-page":"114120","DOI":"10.1016\/j.ejca.2024.114120","volume":"207","author":"R Caroline","year":"2024","unstructured":"Caroline R, Brian G, Helen G, Piotr R, Georgina VL, Marya FC, et al. Open-label, phase II study of talimogene laherparepvec plus pembrolizumab for the treatment of advanced melanoma that progressed on prior anti-PD-1 therapy: MASTERKEY-115. Eur J Cancer. 2024;207:114120.","journal-title":"Eur J Cancer."},{"issue":"5","key":"3863_CR6","doi-asserted-by":"publisher","first-page":"e008999","DOI":"10.1136\/jitc-2024-008999","volume":"12","author":"H Yandong","year":"2024","unstructured":"Yandong H, Xuhong H, Xiaoxia L, Hongwei L, Min L, Junjia T, et al. Preliminary efficacy and safety of YSCH-01 in patients with advanced solid tumors: an investigator-initiated trial. J Immunother Cancer. 2024;12(5):e008999.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"3863_CR7","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1080\/1061186X.2024.2309563","volume":"32","author":"F Xian-Long","year":"2024","unstructured":"Xian-Long F, Xue-Ping C, Jun X, Yun H, Mian C, Hafiz Khuram R, et al. Overview of role of survivin in cancer: expression, regulation, functions, and its potential as a therapeutic target. J Drug Target. 2024;32(3):223\u201340.","journal-title":"J Drug Target."},{"issue":"1","key":"3863_CR8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/sj.onc.1203251","volume":"19","author":"J Fueyo","year":"2000","unstructured":"Fueyo J, Gomez-Manzano C, Alemany R, Lee P, McDonnell T, Mitlianga P, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene. 2000;19(1):2\u201312.","journal-title":"Oncogene"},{"issue":"8","key":"3863_CR9","first-page":"2038","volume":"23","author":"Z Kang-Jian","year":"2016","unstructured":"Kang-Jian Z, Xiao-Fei Y, Yuan-Qin Y, Hui-Ling L, Yan-Ni X, Lie-Yang C, et al. A potent in vivo antitumor efficacy of novel recombinant type I interferon. Clin Cancer Res. 2016;23(8):2038\u201349.","journal-title":"Clin Cancer Res."},{"issue":"3","key":"3863_CR10","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3390\/biomedicines5030046","volume":"5","author":"TV Nguyen","year":"2017","unstructured":"Nguyen TV, Barry ME, Turner MA, Crosby CM, Trujillo MA, Morris JC, et al. Comparison of liver detargeting strategies for systemic therapy with oncolytic adenovirus serotype 5. Biomedicines. 2017;5(3):46.","journal-title":"Biomedicines."},{"issue":"1","key":"3863_CR11","first-page":"vdad117","volume":"5","author":"S Jiang","year":"2023","unstructured":"Jiang S, Chai H-H, Fang X-L, Xu H-S, Li T-W, Tang Q-S, et al. Double-modified oncolytic adenovirus armed with a recombinant interferon-like gene enhanced abscopal effects against malignant glioma. Neurooncol Adv. 2023;5(1):vdad117.","journal-title":"Neurooncol Adv"},{"issue":"3","key":"3863_CR12","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1158\/0008-5472.CAN-05-3497","volume":"66","author":"MA Thomas","year":"2006","unstructured":"Thomas MA, Spencer JF, La Regina MC, Dhar D, Tollefson AE, Toth K, Wold WS. Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors. Cancer Res. 2006;66(3):1270\u20136. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-3497.","journal-title":"Cancer Res."},{"issue":"5","key":"3863_CR13","doi-asserted-by":"publisher","first-page":"648","DOI":"10.4161\/cbt.6.5.4004","volume":"6","author":"X Lin","year":"2007","unstructured":"Lin X, Huang H, Li S, Li H, Li Y, Cao Y, Zhang D, Xia Y, Guo Y, Huang W, Jiang W. A phase I clinical trial of an adenovirus-mediated endostatin gene (E10A) in patients with solid tumors. Cancer Biol Ther. 2007;6(5):648\u201353. https:\/\/doi.org\/10.4161\/cbt.6.5.4004.","journal-title":"Cancer Biol Ther."},{"issue":"9","key":"3863_CR14","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/S1470-2045(13)70274-2","volume":"14","author":"M Westphal","year":"2013","unstructured":"Westphal M, Yl\u00e4-Herttuala S, Martin J, Warnke P, Menei P, Eckland D, Kinley J, Kay R, Ram Z, ASPECT Study Group. Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(9):823\u201333.","journal-title":"Lancet Oncol."},{"issue":"8","key":"3863_CR15","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/cgt.2009.5","volume":"16","author":"DL Lichtenstein","year":"2009","unstructured":"Lichtenstein DL, Spencer JF, Doronin K, Patra D, Meyer JM, Shashkova EV, et al. An acute toxicology study with INGN 007, an oncolytic adenovirus vector, in mice and permissive Syrian hamsters; comparisons with wild-type Ad5 and a replication-defective adenovirus vector. Cancer Gene Ther. 2009;16(8):644\u201354.","journal-title":"Cancer Gene Ther"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-025-03863-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-025-03863-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-025-03863-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T14:22:13Z","timestamp":1751466133000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-025-03863-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["3863"],"URL":"https:\/\/doi.org\/10.1007\/s11095-025-03863-x","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"type":"print","value":"0724-8741"},{"type":"electronic","value":"1573-904X"}],"subject":[],"published":{"date-parts":[[2025,5,8]]},"assertion":[{"value":"3 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by Institutional Animal Care and Use Committee of InnoStar on 1\u2009st January 2022.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Xian-long Fang holds an ownership interest (including patents of YSCH\u201101) in Yuansong Biotechnology Limited Company.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}